title: Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.
abstract: BACKGROUND
  AKT phosphorylation is a critical step in the activation of growth factor receptors and can mediate tumor resistance to anthracyclines. We evaluated the expression patterns and predictive value of phosphorylated AKT (pAKT) in breast cancer tissues.
  
  
  METHODS
  pAKT expression was assessed by immunohistochemistry in 823 tumors from patients with early breast cancer enrolled in two randomized trials. The distribution of pAKT expression was correlated with HER2 and epidermal growth factor receptor (EGFR) expression. The predictive value of pAKT for the efficacy of adjuvant chemotherapy was determined by test for interaction.
  
  
  RESULTS
  pAKT, EGFR, and HER2 were expressed in 119 of 781 (15%), 118 of 758 (16%), and 99 of 775 (13%) assessable tumors. Staining was positive for pAKT in 28 of 99 (28%) and 90 of 676 (13%) HER2+ and HER2- tumors (P < 0.001). pAKT was expressed in 15 of 94 (16%) and 75 of 563 (13%) HER2-/EGFR+ and HER2-/EGFR- tumors, respectively (P = 0.49). A positive staining for pAKT did not correlate with prognosis (P = 0.94), and did not predict the resistance to anthracyclines (test for interaction, P = 0.70).
  
  
  CONCLUSIONS
  AKT phosphorylation is associated with HER2 expression but not EGFR expression in patients with early breast cancer. pAKT is not predictive for the efficacy of anthracycline-based adjuvant chemotherapy.
authors.affiliation: Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: F
authors.initials: F
authors.lastname: Andre
authors.forename: R
authors.initials: R
authors.lastname: Nahta
authors.forename: R
authors.initials: R
authors.lastname: Conforti
authors.forename: T
authors.initials: T
authors.lastname: Boulet
authors.forename: M
authors.initials: M
authors.lastname: Aziz
authors.forename: L X H
authors.initials: LX
authors.lastname: Yuan
authors.forename: F
authors.initials: F
authors.lastname: Meslin
authors.forename: M
authors.initials: M
authors.lastname: Spielmann
authors.forename: G
authors.initials: G
authors.lastname: Tomasic
authors.forename: L
authors.initials: L
authors.lastname: Pusztai
authors.forename: G N
authors.initials: GN
authors.lastname: Hortobagyi
authors.forename: S
authors.initials: S
authors.lastname: Michiels
authors.forename: S
authors.initials: S
authors.lastname: Delaloge
authors.forename: F J
authors.initials: FJ
authors.lastname: Esteva
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D016009:Chi-Square Distribution; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011336:Probability; D016016:Proportional Hazards Models; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism*; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D018570:Risk Assessment; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome